Injection of intravenous immunoglobulin (IVIg) for the treatment of Coronavirus induced cytokine storm

Injection of intravenous immunoglobulin (IVIg) for the treatment of Coronavirus induced cytokine storm

Background. COVID-19 disease is the cause of daily morbidity and mortality worldwide due to its high transmissibility and pathogenicity. To date, intravenous immunoglobulin (IVIg) injection has been used as one of the various treatments for this disease. This study aimed to determine the effect of I...

Full description

Bibliographic Details
Main Authors:	Farahnoosh Farnood, Hamed Valizadeh, Khalil Ansarin, Sepideh Zununi Vahed, Seyyed Sina Hejazian, Armin Sadeghi, Leila Namvar, Farid Rashidi, Seyyedeh Mina Hejazian, Mohammadreza Ardalan, Akbar Sharifi
Format:	Article
Language:	fas
Published:	Tabriz University of Medical Sciences 2022-12-01
Series:	مجله پزشکی دانشگاه علوم پزشکی تبریز
Subjects:	intravenous immunoglobulin (ivig) coronavirus cytokine storm immunoglobulin g (igg) covid-19
Online Access:	https://mj.tbzmed.ac.ir/PDF/mj-44-403.pdf

Similar Items

The therapeutic window of intravenous immunoglobulin (IVIG) and its correlation with clinical outcomes in Kawasaki disease: a systematic review and meta-analysis
by: Zheng Li, et al.
Published: (2023-04-01)

Intravenous immunoglobulins (IVIG) in severe/critical COVID-19 adult patients
by: Dorota Kwapisz, et al.
Published: (2023-07-01)

Mechanism of increased efficacy of recombinant Fc‐μTP‐L309C compared to IVIg to ameliorate mouse immune thrombocytopenia
by: Bonnie J.B. Lewis, et al.
Published: (2021-11-01)

Efficacy of intravenous immunoglobulin (IVIg) on COVID-19-related neurological disorders over the last 2 years: an up-to-date narrative review
by: Paolo Manganotti, et al.
Published: (2023-04-01)

Paediatric Acute-onset Neuropsychiatric Syndrome (PANS) and intravenous immunoglobulin (IVIG): comprehensive open-label trial in ten children
by: Parisa Hajjari, et al.
Published: (2022-08-01)

Comparison of Intravenous Immunoglobulin (IVIG) and Intravenous anti-D for Treatment of Acute Idiopathic Thrombocytopenic Purpura
by: Zahra Farahmandinia, et al.
Published: (2010-10-01)

Comparison of Intravenous Immunoglobulin (IVIG) and Intravenous anti-D for Treatment of Acute Idiopathic Thrombocytopenic Purpura
by: Zahra Farahmandinia, et al.
Published: (2010-12-01)

Timing of infections in patients with primary immunodeficiencies treated with intravenous immunoglobulin (IVIg)
by: Parwinder K. Gill, et al.
Published: (2018-08-01)

Study on the Treatment of ITP Mice with IVIG Sourced from Distinct Sex-Special Plasma (DSP-IVIG)
by: Wei Zhang, et al.
Published: (2023-11-01)

Potential intravenous immunoglobulin-induced optic disc edema
by: Anna K. Britton, et al.
Published: (2022-09-01)

Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs
by: Stephan von Gunten, et al.
Published: (2023-03-01)

Pregnancy associated anti-TIF1 dermatomyositis responsive to intravenous immunoglobulin
by: Jason Kieffer, MD, et al.
Published: (2024-03-01)

Immunoglobulin replacement therapies in inborn errors of immunity: a review
by: Archan Sil, et al.
Published: (2024-02-01)

A Systematic Review and Meta-Analysis of Immunoglobulin G Abnormalities and the Therapeutic Use of Intravenous Immunoglobulins (IVIG) in Autism Spectrum Disorder
by: Daniel A Rossignol, et al.
Published: (2021-05-01)

Immunoglobulin utilization in Canada: a comparative analysis of provincial guidelines and a scoping review of the literature
by: Megan Harmon, et al.
Published: (2023-09-01)

Neuroprotective Effect of Polyvalent Immunoglobulins on Mouse Models of Chemotherapy-Induced Peripheral Neuropathy
by: Mohamad Mroué, et al.
Published: (2024-01-01)

Corrigendum: MIS-C Treatment: Is IVIG Always Necessary?
by: Francesco Licciardi, et al.
Published: (2022-02-01)

Transient lymphadenopathy during intravenous immunoglobulin (IVIg) in a patient with pemphigus vulgaris
by: Delila Pouldar Foulad, et al.
Published: (2021-09-01)

IVIG – A cure to severe refractory NAP-1 Clostridium difficile colitis? A case of successful treatment of severe infection, which failed standard therapy including fecal microbiota transplants and fidaxomicin
by: Kelley Coffman, et al.
Published: (2017-01-01)

Using the K/BxN mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation of potential immunoglobulin-based therapeutic agents, including IVIg and Fc-μTP-L309C, a recombinant IgG1 Fc hexamer
by: Bonnie J. B. Lewis, et al.
Published: (2019-12-01)

Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection
by: Steven Rockman, et al.
Published: (2017-05-01)

Intravenous immunoglobulin remain a source of bias in the interpretation of infectious disease serology among clinicians
by: A.K. Van der Bij, et al.
Published: (2020-12-01)

Predictive value of albumin for intravenous immunoglobulin resistance in a large cohort of Kawasaki disease patients
by: Rui Zhang, et al.
Published: (2023-06-01)

Remarkable benefits of intravenous immunoglobulin (IVIG) in a patient with polymyositis-associated acute interstitial lung disease
by: Soran Peshbahar, et al.
Published: (2020-01-01)

Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial
by: Saori Fukui, et al.
Published: (2021-07-01)

Intravenous Immunoglobulin Therapy for Critically Ill COVID-19 Patients With Different Inflammatory Phenotypes: A Multicenter, Retrospective Study
by: Yan Chen, et al.
Published: (2022-01-01)

Intravenous Immunoglobulins as Immunomodulators in Autoimmune Diseases and Reproductive Medicine
by: Tsvetelina Velikova, et al.
Published: (2023-03-01)

Intravenous Immunoglobulin Therapy in Myocarditis
by: Amir Hossein Mansourabadi, et al.
Published: (2020-08-01)

Cost-minimisation analysis of plasma exchange versus IVIg in the treatment of autoimmune neurological conditions
by: Tara Klemencic Kozul, et al.
Published: (2022-07-01)

The Natural History of Untreated Primary Hypogammaglobulinemia in Adults: Implications for the Diagnosis and Treatment of Common Variable Immunodeficiency Disorders (CVID)
by: Rohan Ameratunga, et al.
Published: (2019-07-01)

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
by: Jolles S
Published: (2013-09-01)

Coronary spastic angina after the administration of intravenous immunoglobulin in myasthenia gravis: a case report
by: Masaru Yanagihashi, et al.
Published: (2020-08-01)

Prescribing Practices of Intravenous Immunoglobulin in Tertiary Care Hospitals in Malaysia: A Need for a National Guideline for Immunoglobulin Use
by: Jian Lynn Lee, et al.
Published: (2022-06-01)

Human Intravenous Immunoglobulin Alleviates Neuropathic Symptoms in a Rat Model of Paclitaxel-Induced Peripheral Neurotoxicity
by: Cristina Meregalli, et al.
Published: (2021-01-01)

Abrogation of neutrophil inflammatory pathways and potential reduction of neutrophil-related factors in COVID-19 by intravenous immunoglobulin
by: Jorge Adrian Masso-Silva, et al.
Published: (2022-10-01)

Decreased Steroid Hormone Receptor NR4A2 Expression in Kawasaki Disease Before IVIG Treatment
by: Ying-Hsien Huang, et al.
Published: (2019-02-01)

Immunoglobulin: production, mechanisms of action and formulations
by: Marcia Cristina Zago Novaretti, et al.
Published: (2011-10-01)

Aseptic meningitis after intravenous immunoglobulin (IVIG) infusion in children with immune thrombocytopenic purpura (ITP)
by: A Tamaddoni, et al.
Published: (2001-04-01)

"High Doses Intravenous Immunoglobulin versus Oral Cyclosporine in the Treatment of Severe Atopic Dermatitis "
by: "Mohammad Hassan Bemanian, et al.
Published: (2005-09-01)

Low-dose immunoglobulin G is not associated with mortality in patients with sepsis and septic shock
by: Yusuke Iizuka, et al.
Published: (2017-07-01)